Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | KYNU | Q16719 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL27980123 | 0.84 | KMT2A (0.59) | KMT2AALOX15BLMPMP22LTA4H | |
| D-Glutamate SCHEMBL28908581 | 0.84 | GRM8 (0.56) | KMT2AALOX15BLMPMP22LTA4H | |
| L-Kynurenine SCHEMBL29415716 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| Kynurenine SCHEMBL20874 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| Kynurenine SCHEMBL29349989 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| Kynurenine SCHEMBL288988 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| L-Kynurenine SCHEMBL288989 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| Kynurenine SCHEMBL2181581 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| L-Kynurenine SCHEMBL13969610 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 | |
| L-Kynurenine SCHEMBL20875 | 0.83 | KDM4E (0.64) | KYNUGRIK1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611502-B2 | Method for simultaneously measuring activity of various enzymes by using multi-wavelength absorption single channel | CHONGQING MEDICAL UNIVERSITY (CN) | 2017-04-04 | — | — | US | disclosed |
| US-20150225764-A1 | METHOD FOR SIMULTANEOUSLY MEASURING ACTIVITY OF VARIOUS ENZYMES BY USING MULTI-WAVELENGTH ABSORPTION SINGLE CHANNEL | CHONGQING MEDICAL UNIVERSITY (CN) | 2015-08-13 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-4603107-A | SIMUTANEOUSLY REACTING WITH GLUTAMYLARYLAMIDE, THEN OXIDIZER AND COUPLING AGENT TO GIVE COLORED COMPOUND | BOEHRINGER MANNHEIM GMBH (DE) | 1986-07-29 | — | — | US | disclosed |
| EP-0103823-A2 | Method and reagent for the determination of gamma-glutamyltransferase | Roche Diagnostics GmbH (DE) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | KMT2A 3666/4885ALOX15 1607/4885BLM 4214/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | KMT2A 4292/4885ALOX15 953/4885BLM 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.